Vociprotafib

Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772) -sensitive EGFR-mutant tumors of mice[1][2][3].

Product Specifications

CAS Number

[2172652-48-9]

Product Name Alternative

RMC-4630; SHP2-IN-7

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Phosphatase; SHP2

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vociprotafib.html

Purity

99.70

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

N[C@H]1C2(CO[C@H]1C)CCN(C3=NC(C)=C(SC4=CC=NC(N)=C4Cl)N=C3CO)CC2

Molecular Formula

C20H27ClN6O2S

Molecular Weight

450.99

Precautions

H302, H315, H319

References & Citations

[1]WO2018013597|[2]Ou S I, et al. A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial[J]. Journal of Thoracic Oncology, 2020, 15 (2) : S15-S16.|[3]Smith J A, et al. SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway[J]. Cancer Research, 2020, 80 (16_Supplement) : 1943-1943.